

Prot. n. 21/DG

Rome, 15/01/2026

Estemeed

BioReliance Ltd.

Glasgow, Scotland, at Unit 5, Todd Campus,
West of Scotland Science Park, G20 0XA

Mail: christiane.hill@merckgroup.com

Subject: Amendment to the Contract for the provision of the Cell Line Characterization Service, according to standard protocols and standard reports in accordance with GMP regulations and aimed at the release of a 3T3 mouse embryonic fibroblast cell bank to be used as a feeder layer in the production of a gene therapy product indicated for the treatment of patients affected by recessive dystrophic epidermolysis bullosa caused by loss-of-function mutations in the COL7A1 gene, which encodes type VII collagen, i.e. the constituent of the anchoring fibrils that ensure dermo-epidermal adhesion for research activities at the Tumor Gene Therapy Research Unit, belonging to the Oncohematology Research Area of the Bambino Gesù Pediatric Hospital.

CUP Code E83C22006230001


Please be advised that with reference to Contract Prot. No. 480/DG of 29/10/2025 relating to the direct award procedure pursuant to art. 50, paragraph 1, letter b), of Legislative Decree 36/2023, concerning the following supply:

- **Cell line characterization service, according to standard protocols and standard reports in accordance with GMP regulations and aimed at the release of a 3T3 mouse embryonic fibroblast cell bank to be used as a feeder layer in the production of a gene therapy product indicated for the treatment of patients affected by recessive dystrophic epidermolysis bullosa caused by loss-of-function mutations in the COL7A1 gene, which encodes type VII collagen, i.e. the constituent of the anchoring fibrils that ensure dermo-epidermal adhesion for research activities at the Tumor Gene Therapy Research Unit, belonging to the Oncohematology Research Area of the Bambino Gesù Pediatric Hospital**

The payment terms for the supply in question set forth in the preamble and in Article 7 of the aforementioned Contract shall be deemed superseded and revised as follows:

- 30% invoiced upon the start of the workshop;
- 50% invoiced upon completion of the workshop, which must be completed no later than March 30, 2026;
- 20% invoiced no later than April 30, 2026.

Bambino Gesù Children's Hospital
General Director
Antonio Perno



21.1.2026

Rome,

For acceptance:

BioReliance Ltd.
Legal Representative

Alison Armstrong

Alison Armstrong

[Alison Armstrong \(22-Jan-2026 11:17:11 GMT\)](#)

22-Jan-2026